Belimumab

Der Hautarzt - Tập 63 - Trang 253-255 - 2012
R. Gläser1
1Hautklinik, Universitätsklinik Schleswig-Holstein, Campus Kiel, Kiel, Deutschland

Tài liệu tham khảo

Wallace DJ (2010) Advances in drug therapy for systemic lupus erythematosus. BMJ Med 8:77. http://www.biomedcentral.com/1741-7015/8/77

Dubey AK, Handu SS, Sharma P et al (2011) Belimumab: First targeted biological treatment for systemic lupus erythematosus. J Pharmacol Pharmacother 2:317–319

Tanou-Stavraki A, Sawalha AH (2011) An update on belimumab for the treatment of lupus. Biologics 5:33–43

Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythamtosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731

Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930

Manzi S, Sanchez-Guerrero J, Merrill JT et al (2010) Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum 62(Suppl 10):607

Albrecht J, Werth VP (2010) Clinical outcome measures for cutaneous lupus erythematosus. Lupus 19:1137–1143

Thông tin
Thông tin xuất bản

Der Hautarzt

Tập 63

253-255

Thông tin tác giả